Spelling suggestions: "subject:"cyclooxygenase 1""
1 |
Pathologic effects of uremia in the kidney and brainRussell, Teresa Lynn 09 June 2020 (has links)
Chronic kidney disease (CKD), a reduction in kidney function, has reached pandemic proportions and imposes a major healthcare burden worldwide. A hallmark of CKD is the accumulation of several chemical compounds, called uremic toxins, which inflict systemic and renal-specific damage. Of the known uremic toxins, kynurenine (Kyn) is known to be particularly vasculotoxic and is implicated in several complications of CKD. Indoleamine 2,3-dioxygenase 1 (IDO), which catalyzes the first step in the metabolism of Tryptophan (Trp), regulates immune response to inflammatory cytokines in tissues. IDO plays a role in apoptosis and damage during acute kidney injury (AKI), a transient decrease in kidney function. During metabolism of Trp, IDO generates Kyn, a uremic solute, and therefore IDO may play a role in the brain and kidney damage due to accumulation of Kyn. The objective of the current study was to investigate the role and regulation of IDO in CKD pathology. Studies were performed to determine whether IDO is protective or pathologic and to find how IDO is regulated in the kidney during CKD. IDO in renopathology was examined using murine models of CKD. CKD was induced via a 0.2% adenine-supplemented diet (AD) model for 21 days. IDO regulation was examined using an Indoxyl Sulfate (IS)-specific solute model. Renal function in the IDO+/+ and IDO-/- AD mice was assessed through weekly measurement of blood urea nitrogen (BUN). H&E and Masson’s trichrome stains were used to assess percentages of glomerulosclerosis (GS) and immune infiltration (II), and combined interstitial fibrosis and tubular atrophy (IFTA) score in IDO+/+ and IDO-/- mice with and without CKD. IDO protein concentration in the kidneys of all mice with and without CKD and IDO+/+ IS mice was determined via immunoblotting. Patients with kidney disease suffer from neuropsychological disorders and neurocognitive decline. The effects of uremic solutes on the CNS was examined using immortalized human umbilical endothelial vein cells (HUVEC-TERT), in vitro. Cell proliferation and viability, in the presence of IS, were measured by BrdU and Alamar blue assays, respectively. In both IDO+/+ and IDO-/-, 21 days of AD results in significant deterioration of renal function. The average IFTA score and percentage of II in IDO-/- mice increased with AD compared to ND (p<0.05, p<0.001). IDO expression was seen sporadically in the glomeruli and walls of major vessels in the kidneys of 4d AD IDO+/+ mice, and in the tubules and vessel walls in the kidneys of 14d AD IDO+/+ mice. In IDO+/+ ND mice, endogenous IDO protein expression was undetectable at a signal intensity of 119.86 ± 268.01, whereas IDO+/+ AD mice showed a 370-fold higher level of IDO protein expression compared to IDO+/+ ND (p<0.001). IDO-/- AD IDO protein expression was 9.5-fold higher than in IDO-/- AD (p<0.05). IDO expression was found to be 58-fold higher in IDO+/+ mice with IS treatment (p<0.05). In the IS mice, non-significant trends toward decrease in cellular proliferation and viability with time were also observed (p=ns). IDO is upregulated at the protein level both in a CKD model and directly by the uremic solute, IS. IDO appears to be protective in the kidney during CKD, given the trend toward increased percentage of GS and II in IDO-/- compared to IDO+/+ mice with CKD, though there is little difference seen in total kidney IFTA. IDO upregulation is linked to increased apoptosis. Blocking uremic solute production would therefore prevent IDO protein upregulation and reduce apoptosis, alleviating renal damage during CKD.
|
2 |
Gene therapy of atopic dermatitis and cancer by sustained expression of interferon-γ in mice / マウスにおける持続的なインターフェロン-γ発現によるアトピー性皮膚炎および癌の遺伝子治療Watcharanurak, Kanitta 24 September 2013 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(薬学) / 甲第17862号 / 薬博第793号 / 新制||薬||236(附属図書館) / 30682 / 京都大学大学院薬学研究科医療薬科学専攻 / (主査)教授 髙倉 喜信, 教授 橋田 充, 教授 佐治 英郎 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DFAM
|
3 |
Avaliação dos metabólitos do triptofano e do polimorfismo do gene da indoleamina 2,3-dioxigenase 1 (IDO1) na etiopatogênese da artrite reumatoide / Evaluation of tryptophan metabolites and indoleamine 2,3- dioxygenase 1 (IDO1) gene polymorphism in rheumatoid arthritis etiopathogenesisLôbo, Patricia Rolim Mendonça 21 June 2018 (has links)
A artrite reumatoide (AR) é a artropatia inflamatória mais prevalente no mundo, de etiologia multifatorial e fenótipos heterogêneos. Busca-se, além de definir fatores etiológicos, compreender as interações entre mecanismos envolvidos na fisiopatologia da AR. Entre estes, fatores genéticos, tanto genes do antígeno leucocitário humano (HLA), especialmente a presença do epítopo compartilhado (Shared epitope - SE) do HLA-DRB1, como genes não-HLA, e fatores ambientais e epigenéticos têm sido associados à doença. Assim, a identificação de novos fatores relacionados à etiopatogenia da AR e suas possíveis associações com características clínicas motivaram esse estudo. Um estudo caso-controle foi desenhado e dividido em duas etapas. Para a primeira etapa, foi obtido plasma de 18 indivíduos de AR e 18 voluntários saudáveis de Ribeirão Preto, no qual foram identificados quinurenina (Kyn), Trp, serotonina (5-HT) e taxa Kyn/Trp (KTR) por cromatografia líquida de ultra-eficiência (CLUE) acoplada a espectrômetro de massas sequencial (CLUE-DAD-EM/EM). Na segunda etapa, de estudo genético, uma coorte formada por 328 indivíduos com AR e por 234 voluntários saudáveis de Ribeirão Preto e de Porto Alegre foi avaliada quanto ao polimorfismo do gene da enzima indoleamine 2,3-dioxigenase 1 (IDO1). Foram obtidos dados clínicos e epidemiológicos e coletadas amostras de sangue periférico para extração de DNA pelo método de salting-out. Em seguida, tipificação HLA e reação em cadeia de polimerase (RCP) das variantes da IDO1, rs7820268, rs3739319, rs61753677, rs35059413, rs35099072 e rs9298586, foram realizadas. A positividade para fator reumatoide (FR) em indivíduos com AR foi associada ao tabagismo (p= 0.0002) e ao SE (p < 0.0001), e para anticorpo antipeptídeo citrulinado cíclico (anti-CCP), associado ao SE (p < 0.0001). Quando combinadas a presença de SE e a de tabagismo, houve associação estatisticamente significante para FR (p < 0.001) e para anti-CCP (p = 0.03). Foram observadas menores concentrações plasmáticas de 5-HT em indivíduos com AR quando comparados a voluntários saudáveis (p =0.006), mas sem diferença para níveis de Trp, Kyn e KTR. Para estes, diferenças apareceram quando avaliados subgrupos. Em indivíduos com AR sem tratamento com drogas modificadoras do curso da doença (DMCDs), os valores plasmáticos de Trp foram menores quando comparados aos em terapia (p = 0.0016), enquanto em pacientes com AR tabagistas os valores de Kyn e KTR foram menores que em pacientes não tabagistas (p = 0.039 e p = 0.032, respectivamente). Não foram identificadas associações estatisticamente significantes entre as variantes genéticas estudadas e o risco de desenvolver AR, nem entre os polimorfismos da IDO1 estudados e a concentração plasmática de Trp, Kyn e 5-HT e KTR. Este estudo não identificou relação das variantes do gene da IDO1 com suscetibilidade para AR. Assim, novos estudos são necessários para que possam ser explicadas as associações encontradas na via das Kyns e na 5-HT em etiopatogenia da AR. / Rheumatoid arthritis (RA) is the most prevalent inflammatory arthropathy in the world, with multifactorial etiology and heterogeneous phenotypes. Besides defining etiological factors, it is sought to understand the interactions between mechanisms in RA pathophysiology. About these, genetic factors, both human leucocity antigen (HLA) genes, especially the HLA-DRB1 Shared epitope (SE) presence, and not-HLA genes, and environmental and epigenetics factors have been associated with the disease. Therefore, the aim of this study was to identify new possible associations between RA clinical features and its etiopathogenesis. A case-control study was designed and it was divides in two phases. The first phase, it was obtained plasma of 18 RA patients and 18 healthy controls from Ribeirão Preto to identify the kynurenine (Kyn), Trp and serotonin (5-HT) concentrations and Kyn/Trp ratio (KTR) by ultra-high performance liquid chromatography coupled to sequential mass spectrometer. The second phase was a genetic study that evaluated a cohort of 328 RA patients and 234 healthy volunteers from Ribeirão Preto and Porto Alegre about the indoleamine 2,3-dioxygenase 1 (IDO1) gene polymorphism. Clinical and epidemiological data were obtained and peripheral blood samples were collected to DNA extraction by salting-out method. Then, HLA typification and polymerase chain reaction to identify IDO1 genetic variants rs7820268, rs3739319, rs61753677, rs35059413, rs35099072 and rs9298586 were performed. Rheumatoid factor (RF) positivity was associated to smoking (p = 0.0002) and SE (p < 0.0001), and cyclic citrullinated peptide autoantibodies (anti-CCP) positivity was associated to SE (p < 0.0001). When SE presence and smoking were combined, there was statistically significant association to RF (p < 0.001) and anti-CCP (p = 0.03). We observed lower plasma 5-HT concentrations in RA patients than in healthy volunteers (p = 0.006), but no significant difference to Trp, Kyn and KTR levels. For these, differences were observed when subgroups were evaluated. In RA patients not using disease modifying antirheumatic drugs (DMARDs) the plasma Trp levels were lower than RApatients using DMARDs, while the plasma Kyn concentrations and KTR in smokers RA patients were lower than nonsmokers RA patients (p = 0.039 and p = 0.032 respectively). We did not indetify statistically significant associations neither between studied genetic variants and risk to develop RA nor between IDO1 polymorphisms and plasma Trp, Kyn, 5HT concentrations and KTR. This study did not identify relation between IDO1 genetic variants with susceptibility to RA. Therefore, new studies are necessary to explain the searched associations between Kyns pathway and 5-HT in RA etiopathogenenesis.
|
4 |
Avaliação dos metabólitos do triptofano e do polimorfismo do gene da indoleamina 2,3-dioxigenase 1 (IDO1) na etiopatogênese da artrite reumatoide / Evaluation of tryptophan metabolites and indoleamine 2,3- dioxygenase 1 (IDO1) gene polymorphism in rheumatoid arthritis etiopathogenesisPatricia Rolim Mendonça Lôbo 21 June 2018 (has links)
A artrite reumatoide (AR) é a artropatia inflamatória mais prevalente no mundo, de etiologia multifatorial e fenótipos heterogêneos. Busca-se, além de definir fatores etiológicos, compreender as interações entre mecanismos envolvidos na fisiopatologia da AR. Entre estes, fatores genéticos, tanto genes do antígeno leucocitário humano (HLA), especialmente a presença do epítopo compartilhado (Shared epitope - SE) do HLA-DRB1, como genes não-HLA, e fatores ambientais e epigenéticos têm sido associados à doença. Assim, a identificação de novos fatores relacionados à etiopatogenia da AR e suas possíveis associações com características clínicas motivaram esse estudo. Um estudo caso-controle foi desenhado e dividido em duas etapas. Para a primeira etapa, foi obtido plasma de 18 indivíduos de AR e 18 voluntários saudáveis de Ribeirão Preto, no qual foram identificados quinurenina (Kyn), Trp, serotonina (5-HT) e taxa Kyn/Trp (KTR) por cromatografia líquida de ultra-eficiência (CLUE) acoplada a espectrômetro de massas sequencial (CLUE-DAD-EM/EM). Na segunda etapa, de estudo genético, uma coorte formada por 328 indivíduos com AR e por 234 voluntários saudáveis de Ribeirão Preto e de Porto Alegre foi avaliada quanto ao polimorfismo do gene da enzima indoleamine 2,3-dioxigenase 1 (IDO1). Foram obtidos dados clínicos e epidemiológicos e coletadas amostras de sangue periférico para extração de DNA pelo método de salting-out. Em seguida, tipificação HLA e reação em cadeia de polimerase (RCP) das variantes da IDO1, rs7820268, rs3739319, rs61753677, rs35059413, rs35099072 e rs9298586, foram realizadas. A positividade para fator reumatoide (FR) em indivíduos com AR foi associada ao tabagismo (p= 0.0002) e ao SE (p < 0.0001), e para anticorpo antipeptídeo citrulinado cíclico (anti-CCP), associado ao SE (p < 0.0001). Quando combinadas a presença de SE e a de tabagismo, houve associação estatisticamente significante para FR (p < 0.001) e para anti-CCP (p = 0.03). Foram observadas menores concentrações plasmáticas de 5-HT em indivíduos com AR quando comparados a voluntários saudáveis (p =0.006), mas sem diferença para níveis de Trp, Kyn e KTR. Para estes, diferenças apareceram quando avaliados subgrupos. Em indivíduos com AR sem tratamento com drogas modificadoras do curso da doença (DMCDs), os valores plasmáticos de Trp foram menores quando comparados aos em terapia (p = 0.0016), enquanto em pacientes com AR tabagistas os valores de Kyn e KTR foram menores que em pacientes não tabagistas (p = 0.039 e p = 0.032, respectivamente). Não foram identificadas associações estatisticamente significantes entre as variantes genéticas estudadas e o risco de desenvolver AR, nem entre os polimorfismos da IDO1 estudados e a concentração plasmática de Trp, Kyn e 5-HT e KTR. Este estudo não identificou relação das variantes do gene da IDO1 com suscetibilidade para AR. Assim, novos estudos são necessários para que possam ser explicadas as associações encontradas na via das Kyns e na 5-HT em etiopatogenia da AR. / Rheumatoid arthritis (RA) is the most prevalent inflammatory arthropathy in the world, with multifactorial etiology and heterogeneous phenotypes. Besides defining etiological factors, it is sought to understand the interactions between mechanisms in RA pathophysiology. About these, genetic factors, both human leucocity antigen (HLA) genes, especially the HLA-DRB1 Shared epitope (SE) presence, and not-HLA genes, and environmental and epigenetics factors have been associated with the disease. Therefore, the aim of this study was to identify new possible associations between RA clinical features and its etiopathogenesis. A case-control study was designed and it was divides in two phases. The first phase, it was obtained plasma of 18 RA patients and 18 healthy controls from Ribeirão Preto to identify the kynurenine (Kyn), Trp and serotonin (5-HT) concentrations and Kyn/Trp ratio (KTR) by ultra-high performance liquid chromatography coupled to sequential mass spectrometer. The second phase was a genetic study that evaluated a cohort of 328 RA patients and 234 healthy volunteers from Ribeirão Preto and Porto Alegre about the indoleamine 2,3-dioxygenase 1 (IDO1) gene polymorphism. Clinical and epidemiological data were obtained and peripheral blood samples were collected to DNA extraction by salting-out method. Then, HLA typification and polymerase chain reaction to identify IDO1 genetic variants rs7820268, rs3739319, rs61753677, rs35059413, rs35099072 and rs9298586 were performed. Rheumatoid factor (RF) positivity was associated to smoking (p = 0.0002) and SE (p < 0.0001), and cyclic citrullinated peptide autoantibodies (anti-CCP) positivity was associated to SE (p < 0.0001). When SE presence and smoking were combined, there was statistically significant association to RF (p < 0.001) and anti-CCP (p = 0.03). We observed lower plasma 5-HT concentrations in RA patients than in healthy volunteers (p = 0.006), but no significant difference to Trp, Kyn and KTR levels. For these, differences were observed when subgroups were evaluated. In RA patients not using disease modifying antirheumatic drugs (DMARDs) the plasma Trp levels were lower than RApatients using DMARDs, while the plasma Kyn concentrations and KTR in smokers RA patients were lower than nonsmokers RA patients (p = 0.039 and p = 0.032 respectively). We did not indetify statistically significant associations neither between studied genetic variants and risk to develop RA nor between IDO1 polymorphisms and plasma Trp, Kyn, 5HT concentrations and KTR. This study did not identify relation between IDO1 genetic variants with susceptibility to RA. Therefore, new studies are necessary to explain the searched associations between Kyns pathway and 5-HT in RA etiopathogenenesis.
|
Page generated in 0.0519 seconds